MedPath

The Proton Pump Inhibitor (PPI) Test for the Extraesophageal Manifestation of GERD

Not Applicable
Conditions
Gastroesophageal Reflux Disease
Registration Number
NCT00539786
Lead Sponsor
Samsung Medical Center
Brief Summary

PPI test;empirical trial with high-dose proton-pump inhibitors (PPIs) has been shown to be a sensitive tool for diagnosing patients with GERD. However, this diagnostic strategy has not been well established in patients with extraesophageal manifestation of GERD. In this study, we aim to see the relevance of PPI test in diagnosing GERD in patients with extraesophageal symptoms.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
100
Inclusion Criteria
  • Patients with extraesophageal manifestation symptoms of GERD
Exclusion Criteria
  • laryngeal, pharyngeal, liver, lung, renal, or hematological disorders
  • a history of gastrointestinal surgery, and a history of connective tissue disorders.
  • patients with duodenal or gastric ulcers as well as other significant lesions, such as gastric cancer, esophageal cancer, or subepithelial tumors more than 1 cm observed on the upper endoscopy

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Symptom responders after PPI trials2 weeks after PPI trials
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Samsung Medical Center, Sungkyunkwan University School of Medicine

🇰🇷

Seoul, Gangnam-gu, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath